Headlines Covid-19 Specialties Trending Feeds Videos

Dr. Emil Lou and Dr. Muhammad Shaalan Beg, of ASCO’s Social Media Working Group, explore the role and reach of Twitter and Instagram during...

2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved...

e19332 Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment...

e21664 Background: Hyperprogressive disease (HPD) is a new pattern of progressión during immunotherapy and is described as an acceleration of tumor growth during treatment...

2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved...

e19332 Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment...

2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved...

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary...

This randomized clinical trial assesses the efficacy and safety of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced squamous...

  • #OncoAlert Results from the phase III RATIONALE 307 trial of tislelizumab (anti-PD1) plus 1L chemo vs chemo alone in squamous NSCLC @JAMAOnc. Interim results were presented at #ASCO20. With full results, tislelizumab was approved in China 1/13/21. #LCSM https://t.co/nEBzzuIaju - view on twitter

In the United States, many cancer centers advertise their clinical services directly to the public. Although there are potential public benefits from such advertising,...